PRECIGEN, INC. Stock Split Ratio
PRECIGEN, INC. (PGEN) reported Stock Split Ratio of 57.14% for the 1-month period ending 2013-07-26, per its 10-K filed 2015-03-02.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2015-03-02
- 2013-07-26: Stockholders' Equity Note, Stock Split, Conversion Ratio 57.14%; Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 57.14%; Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month as first filed 57.14%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month as first filed |
|---|---|---|---|
| 2013-07-26 | 57.14% 10-Q · filed 2014-08-14 | 57.14% 10-K · filed 2015-03-02 | 57.14% 10-Q · filed 2013-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |